April #69 : Two Strikes

POZ - Health, Life and HIV
Subscribe to:
POZ magazine
E-newsletters
Join POZ: Facebook MySpace Twitter Pinterest
Tumblr Google+ Flickr MySpace
POZ Personals
Sign In / Join
Username:
Password:

Back to home » Archives » POZ Magazine issues




Table of Contents

Geography Lessons

Mo' Money, Mo' Trouble

Cold Sore Comfort

THE BIZ OF AID$

Living Large on Small Change

Living Large on Small Change

Living Large on Small Change

O Pioneer!

Going Dental

Vax Attack

¡La Emergencia!

Monette & Merrill

Normal, New Jersey

Briefs

Milestones

Quickies

Money Pit

Cryptic 'Script

Don't Meth Around

AAT Ease

Two Strikes

LTNP? UB2

Is N-9 Deep-Sixed?

Action Zero

Mary MAC'd

Murphy's Law Breaker

Editor's Letter

Mailbox

04.09.84 The Waters of Babylon

Conflicts in Pharmaland



Most Popular Lessons

The HIV Life Cycle

Shingles

Herpes Simplex Virus

Syphilis & Neurosyphilis

Treatments for Opportunistic Infections (OIs)

What is AIDS & HIV?

Hepatitis & HIV


email print

April 2001

Two Strikes

It's double-whammy time for the non-nuke nevirapine (Viramune). Already known to cause potentiall

It's double-whammy time for the non-nuke nevirapine (Viramune). Already known to cause potentially fatal allergic reactions, including severe skin rash and liver damage, in some takers, substantially increased reports to the Food and Drug Administration (FDA) of such problems prompted a harsher warning to health care providers from manufacturer BoehringerIngelheim/Roxane Laboratories. The company advised close clinical and laboratory monitoring during the first 12 weeks of nevirapine use, when problems are most likely to occur. After that, continued monitoring is recommended because in one third of the cases, the liver problems developed after 12 weeks. HIVers coinfected with hep B or C are at higher risk for bad livers when taking the drug.

A second nevirapine red flag came from the Centers for Disease Control and Prevention (CDC) in January, advising against the drug's use for postexposure prophylaxis (PEP), the anti-HIV prevention measure used immediately after exposure to the virus. Although nevirapine has never been CDC-recommended for PEP, its rapid action, ease of use and effectiveness for single-dose prevention of mother-to-child transmission (still considered safe) led some docs to prescribe it. An FDA review found 22 cases of serious reactions in previously healthy nevirapine PEPers. Distressing symptoms often began after a short time on the drug (two weeks on average).

Although nevirapine-takers' liver symptoms vary, the first commonly include fatigue, appetite loss and nausea, sometimes accompanied by blood liver enzyme elevations, followed by jaundice (yellowing of the eyes and skin), liver swelling and liver failure. Anyone with such symptoms is advised to stop using nevirapine immediately, go for liver tests and, by all means, never take the drug again.




[Go to top]

Join POZ Facebook Twitter Google+ MySpace YouTube Tumblr Flickr
Quick Links
Current Issue

HIV Testing
Safer Sex
Find a Date
Newly Diagnosed
HIV 101
Disclosing Your Status
Starting Treatment
Help Paying for Meds
Search for the Cure
POZ Stories
POZ Opinion
POZ Exclusives
Read the Blogs
Visit the Forums
Job Listings
Events Calendar


    dversescott
    Baltimore
    Maryland


    Loveladyd
    Washington
    DC


    pevans
    San Francisco
    California


    thebake
    Sioux Falls
    South Dakota
Click here to join POZ Personals!
Ask POZ Pharmacist

Talk to Us
Poll
Will decriminalizing injection drug use help end the global HIV epidemic?
Yes
No

Survey
PrEP Course

more surveys
Contact Us
We welcome your comments!
[ about Smart + Strong | about POZ | POZ advisory board | partner links | advertising policy | advertise/contact us | site map]
© 2014 Smart + Strong. All Rights Reserved. Terms of use and Your privacy.
Smart + Strong® is a registered trademark of CDM Publishing, LLC.